Grace Halsey

The newest generic OTC nonprescription naloxone hydrochloride nasal spray provides additional access to the lifesaving treatment, at potentially lower cost.

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.

More participants consuming either of 2 common IBS dietary regimens experienced significant and sustained symptom relief vs those given pharmacotherapy.

Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.

To cover a medical bill, more than half of those surveyed would downsize a home, 75% would take on a second job; more than 1/3 had already skipped care due to costs.

Treatment by female physicians resulted in better 30-day outcomes for male and female patients, but the benefit was significantly greater for the women.

Increased arterial stiffness and elevated central BP are among factors researchers found to have strong discriminatory value for PE at term and postpartum.

Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.

Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.

The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.

Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.

Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.

The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.

Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.

The overall CKD population will reach 125 million by 2032 across 8 industrialized nations, with significant clinical, social, economic, and environmental costs.

AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.

LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.

The AHS recommends the migraine-specific preventive medications be prescribed first, with no requirements to "fail" other treatments for eligibility.

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

New study findings raise important questions about how early to initiate therapy to reduce proteinuria and whether even lower levels should be sought to improve CKD outcomes.

ACC.24: Even modest alcohol intake increases risk for coronary heart disease in men and women but women are at much greater risk across levels of weekly consumption.

Resmetirom to treat NASH with F2-F3 fibrosis, the only approved therapy, is available through Madrigal's specialty pharmacy network, the company said.

The web app showed more than 90% concordance with clinical assessment of eligibility for low dose rosuvastatin; study yields 35.5% reduction in LDL-C.

Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.